GSDME Knockout SK-OV-3 Cell Line

The choice depends on whether you are studying GSDME (DFNA5, gasdermin E)'s role as a caspase-3-cleaved pyroptosis executor or modeling chemotherapy-induced pyroptosis in ovarian cancer. The Knockout line is the standard tool for asking whether GSDME is required for chemotherapy-induced pyroptosis — GSDME is cleaved by activated caspase-3 (downstream of intrinsic apoptosis), releasing the N-terminal pore-forming fragment that punctures the plasma membrane and converts apoptosis into pyroptosis; this 'apoptosis-to-pyroptosis switch' contributes to chemotherapy efficacy in GSDME-high tumors. Overexpression is useful for studying GSDME gain-of-function in cancer contexts. For ovarian cancer research, the EDITGENE GSDME Knockout in SK-OV-3 is highly relevant — SK-OV-3 is an ovarian adenocarcinoma cell line, and GSDME-driven pyroptosis is implicated in chemotherapy response. Rescue with wild-type, caspase-3-cleavage-resistant (D270A), or N-terminal-fragment-only GSDME enables structure-function studies. The knockout is valuable for studying chemotherapy-induced pyroptosis (cisplatin, paclitaxel) given GSDME's role in the apoptosis-pyroptosis switch — GSDME expression has been associated with cancer therapy response and immunogenic cell death.

Primary applications: • Chemotherapy-induced pyroptosis: cisplatin, paclitaxel, or other chemotherapy-induced LDH release and pyroptosis morphology analysis in GSDME-null versus rescued ovarian cancer cells. • Caspase-3 cleavage: GSDME-N (cleaved fragment, ~30 kDa) Western blot to characterize caspase-3-mediated GSDME cleavage during apoptosis-pyroptosis switching. • Immunogenic cell death: HMGB1 release and DAMPs analysis given GSDME-driven inflammatory cell death. • Cancer immunotherapy response: in checkpoint inhibitor combination studies given GSDME's role in immunogenic chemotherapy response. EDITGENE recommends this model for researchers investigating chemotherapy-induced pyroptosis, immunogenic cell death mechanisms, and GSDME-targeted cancer therapeutic strategies.

Yes. GSDME rescue experiments are well-established for pyroptosis research: • Construct design: use a codon-modified GSDME sequence with a small C-terminal tag (FLAG, HA). GSDME has N-terminal pore-forming domain (GSDME-N) and C-terminal auto-inhibitory domain (GSDME-C) linked by a caspase-3 cleavage site (D270) — preserve all elements. • Caspase-3-cleavage-resistant rescue: D270A mutation abolishes caspase-3 cleavage, generating uncleavable GSDME that cannot drive apoptosis-to-pyroptosis switching. • N-terminal-fragment-only rescue: constitutive expression of GSDME-N (residues 1-270) generates auto-induced pyroptosis without requiring caspase activation. • Pore-forming-deficient rescue: GSDME-N membrane-binding residue mutations abolish pore formation. • Functional readout: rescue should restore chemotherapy-induced apoptosis-to-pyroptosis switching measured by LDH release and pyroptosis morphology. SK-OV-3-specific considerations: • SK-OV-3 is a human ovarian adenocarcinoma cell line (HER2-overexpressing, p53-null, TP53 mutant) — widely used in ovarian cancer research and chemotherapy response studies. • Lentiviral transduction is supported with moderate efficiency. • The HER2-overexpressing background makes SK-OV-3 relevant for studying HER2-driven cancer biology and trastuzumab response.